ClinicalTrials.gg
Status unknownNCT03320031Updated Oct 24, 2017

A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy

A Phase 4 interventional study of Linagliptin and Humalog Mix 75/25 in Type 2 Diabetes Mellitus and Peritoneal Dialysis, sponsored by Yanbing Li. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-10-24.

Sponsored by Yanbing Li · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2017), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jun 2017, registered Oct 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
232
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 67 studies testing linagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus, Type 2.

Planned enrollment
30th of 67
232 · median 175
Started
2017
with 1 other
Phase 4
22 of 67
1 open now
Registered
56th of 67
by date

Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, this one is the 30th largest by planned enrollment, is one of 2 that started in 2017, is one of 22 in phase 4, and was the 56th registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 67 studies testing linagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About linagliptin

Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing linagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

In china, there are the most population of type 2 diabetes mellitus (DM) among the world and DM becomes currently the second cause for end-stage renal disease (ESRD). Nearly 50% of insulin-treated PD patients in clinical practice are treated with premixed insulin. Glycemic control in them is very difficult to be achieved mainly due to the uremic status of these patients and glucose exposure from peritoneal dialysate, a higher glycemic variability and higher risk of hypoglycemia. Linagliptin, unlike other DPP-4 inhibitors, has a primarily non-renal elimination route, and does not require dose adjustment for any level of impaired renal function. The aim of this study is to evaluate the effect of linagliptin on glucose variability and glycemic control in peritoneal dialysis patients with type 2 diabetes who are inadequately controlled with premixed insulin therapy.

This will be a randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of linagliptin on glucose variability and glycemic control in peritoneal dialysis patients with type 2 diabetes who are inadequately controlled with premixed insulin therapy.which will be conducted in 8 diabetes centres and/or nephropathy departments in China. After a 4-week run- in period, 232 participants are randomized (1:1) to either premixed insulin combined with linagliptin (5mg/d) group (also named combined group) or premixed insulin alone group (also named insulin group) for 12 weeks. Finally, the primary endpoint is glucose variability indicated by MAGE, secondary endpoints include HbA1c, FPG, PPG, LAGE, SDBG, PT10.0, PT3.9, 1h fasting MBG, 3h postprandial MBG, insulin dosage, hypoglycemia and body weight.

03

Conditions studied

  • Type 2 Diabetes Mellitus
  • Peritoneal Dialysis

Keywords

  • Linagliptin
  • premixedinsulin therapy
  • peritoneal dialysis
  • glycemic variability
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Type 2 diabetic patients who were treated with insulin regimen;
  2. Ages eligible for study:18 years to 80 years;
  3. The patients with end-stage kidney disease receiving a regular peritoneal dialysis for at least 3 months;
  4. ranging from 6.5%-10.5% when screening and randomizing ;
  5. ranging from 21 to 35 kg/m2.

Exclusion criteria

Exclusion Criteria:

  1. Having any severe acute or chronic diabetic complications
  2. Blood aminotransferase level rising up more than 2 times of the upper normal limit
  3. Any severe cardiac disease, severe systemic diseases or malignant tumour
  4. Female patients incline to be pregnant
  5. Being treated with , drugs or cytotoxic drugs
  6. Poor compliance
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
232 participants (estimated)

Study arms

  • Experimental
    combined group

    Drug: linagliptin\&premixed insulin Treated with linagliptin 5mg/d combined with premixed insulin for 12 weeks.

    Drug: Linagliptin · Drug: Humalog Mix 75/25

  • Active comparator
    linsulin group

    Drug: premixed insulin Treated with premixed insulin for 12 weeks.

    Drug: Humalog Mix 75/25

Interventions

  • Take linagliptin 5mg a day.

    Also known as: Trajenta

  • DrugHumalog Mix 75/25

    Administer subcutaneous premixed insulin twice a day.

    Also known as: insulin lispro 75/25

06

What researchers measure

Primary outcomes

  1. glucose variability

    The change from baseline to week 12 in glucose variability indicated by MAGE.

    Time frame: 12 weeks

Secondary outcomes

  1. HbA1c

    Changes in HbA1c between two groups

    Time frame: 12 weeks

  2. FPG

    Changes in FPG between two groups

    Time frame: 12 weeks

  3. insulin dosage

    Changes in FPG at the end between two groups

    Time frame: 12 weeks

  4. body weight

    Changes in body weight at the end between two groups

    Time frame: 12 weeks

  5. hypoglycemia

    Frequency of hypoglycemia at the end in each gropu

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
  • endocrinology department of the first affiliated hospital of Sun Yat-sen University
    Guangzhou, Guangdong 510080, China
    Recruiting
    • Yanbing Li, MD,PhD · Contacteasd04lyb@126.com · 8602087334331
    • Yanbing Li, MD,PhD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2017 (actual). Primary completion is estimated for Dec 2019, 30 months after the start.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 30 months is close to that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2017
First posted
Oct 24, 2017
StartActual
Jun 3, 2017
Primary completionEst.
Dec 2019
CompletionEst.
Dec 2019
Last update
Oct 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03320031
Lead sponsor
Yanbing Li
Responsible party
Yanbing Li (Director of Endocrinology and Metabolism Department, Sun Yat-sen University) — Sponsor-investigator
First posted
Oct 24, 2017
Start date
Jun 3, 2017
Primary completion
Dec 2019 (estimated)
Completion
Dec 2019 (estimated)
Last update
Oct 24, 2017

Study contacts

Yanbing Li, MD,PhD
Contact
easd04lyb@126.com
+86-13925111691
Xueqing Yu
Contact
yuxq@mail.sysu.edu.cn
+86-13802793488

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linagliptin

Start the discussion